As part of our ‘Ask the expert’ series, we heard from neuroscientist and psychiatrist Dr Philip Mosley about the severe impact “behavioural addictions” can have on people with Parkinson’s.
To gain further understanding about why people with Parkinson’s can develop impulsive and compulsive behaviours, Philip contributed to a study which set up a virtual casino for people with the condition. The aim was to explore why some people who take dopaminergic medication struggle with these problems.
“If we can unravel why a problem occurs, or at least explain some of the variability,” he said, “then we can deliver more accurate and personalised information to people with Parkinson’s.” Recognising the added challenges of stigma when it comes to behaviours like gambling, binge eating or hypersexuality, Philip advocates for a “non-judgemental atmosphere” to help people talk freely about these issues.
His advice? “Don’t despair – you can recover from these problems.”
US-based writer Heather Kennedy hadn’t questioned how Parkinson’s might impact her as a woman until she realised how the condition affected menstruation – and she became aware of biased perceptions within the community.
“One thing I’ve noticed in Parkinson’s community is how women are openly shamed for experiencing impulse control disorders to do with sex,” she said. “But when it’s men, you hear that phrase: ‘Boys will be boys’. I just think that dynamic is so wrong.”
Heather herself experienced “hyper compulsion” related to cleaning and shopping. “These drugs are powerful, and they cause major changes in us,” she said. “We need more warning about that.”
These behaviours can manifest in different ways, including “compulsive spending”, says Dr Philip Mosley.
When creating a film about Parkinson’s, UK neuroscientist and writer Jon Stamford knew he wanted to avoid making something too medical or “unfocused”.
“Patients are tired of being lectured to,” he noted. “We wanted to engage with them.” To do this, he partnered with Norwegian filmmaker Anders M Leines to create a series of short films addressing the aspects of Parkinson’s that are rarely discussed openly.
“This lack of discussion, almost a conspiracy of silence, does not serve patients well,” said Jon. “People who suffered from impulse control disorders… can realise that they are not alone, and these aspects can be treated. Openness can only be good.”
When Matt Eagles first started using a ‘dopamine agonist’ (medication which mimics dopamine in the brain), it appeared to be working well. But some 18 months later, he found himself addicted to gambling apps on his phone.
“I’d go to the bathroom just to play on fruit machines, video poker and roulette in secret,” he recalled, “losing the money that my fiancée and I had saved.”
When he admitted the situation to his fiancée, the pair realised he must have been suffering from an impulse control disorder. After seeing a specialist and being weaned off the medication, Matt experienced fewer impulses to gamble. “It was such a relief,” he said.
“The drugs really did help with mobility, so coming off them has meant that my Parkinson’s is worse,” he added. “But it’s a consequence that I’ve learned to live with. The medication was literally ruining my life.”
To learn more about how impulsive and compulsive behaviours can impact people living with Parkinson’s, tune into our upcoming podcast episode on the topic – which will launch on 24 February.
Dopamine agonists for Parkinson’s: a simple introduction
Find out more about Parkinson’s medication
4 hours ago
Could a sea sponge support the search for Parkinson’s disease treatments?
How could a molecule in a sea sponge help treat Parkinson’s and similar conditions? Researchers at the University of California, Los Angeles (UCLA), in the US, recently explored this question. Their findings were published in the journal ‘Science’. The team examined a molecule known as lissodendoric acid A, which appears to counteract other molecules that damage DNA, proteins and whole cells – and was recently discovered in a sea sponge. The research team used an oft-neglected compound called a cyclic allene to control a step in the chain of chemical reactions, which enabled them to create a version of the molecule in a lab. Scientists believe that the ability to synthetically produce lissodendoric acid A will help them assess whether it can inform future therapies for conditions like Parkinson’s. UCLA’s Professor Neil Garg, the corresponding author of the study, said: “We hope others will also be able to use cyclic…
Study finds just six minutes of daily exercise might delay onset of Parkinson’s disease
Regular exercise is a common therapeutic strategy for people with Parkinson’s. Now, a study from New Zealand has suggested that daily physical activity might even delay the onset of this condition. Published in ‘The Physiological Society’, the study focused on a protein called brain-derived neurotrophic factor (BDNF) – which has previously been shown to boost cognitive performance. The researchers assessed the impact of fasting and physical activity on BDNF production in 12 people aged 18 to 56. The tests involved fasting and completing exercises of varying intensity, such as cycling for six minutes, as well as combinations of both fasting and physical activity. The results showed that brief, intense exercise was the best option for increasing the production of BDNF – with the protein increasing by a factor of four to five times compared to light exercise or fasting. Because BDNF can protect the brain from cognitive decline, the findings could…
Machine learning may help predict risk of freezing of gait in Parkinson’s disease
Difficulty taking steps forward, often referred to as the freezing of gait (FOG), is a common symptom experienced by people with Parkinson’s and one that can be difficult to predict. China-based researchers suggest that machine learning – artificial intelligence (AI) that uses algorithms to analyse data – could help predict the risk of freezing of gait developing in the early stages of the condition. Their study, published in ‘npj Parkinson’s Disease’, gave laboratory and clinical data to a machine learning model brain. This information was collected from 158 adults with untreated early-stage Parkinson’s and 73 healthy adults over a five-year period. They found that the risk of FOG could be predicted with an accuracy rate of up to 78%. The study authors suggested that machine learning methods “have the potential to help predict future FOG in patients with early Parkinson’s at an individual level”.